October 26, 2014
ABCDEFGHIJKLMNOPQRSTUVWXYZ

 Health Home >>  >>   

Diabetes drug might also aid weight loss

Provided by: RELAXNEWS
Written by: Relaxnews
Jun. 16, 2014

A new weight management drug is currently being considered for approval in Europe and North America. (AFP PHOTO/William WEST)


Adults who are overweight, obese or have type 2 diabetes might be able to benefit from Danish-made Victoza, which, in its third phase of clinical trials, proved successful in weight management.

Ad
Its chemical name is liraglutide and when given in 3mg doses over a 56-week period, combined with proper diet and exercise, trial participants experienced a 5.9 percent mean loss of baseline body weight.

Smaller doses of the drug led to a slightly reduced mean weight loss of 4.6% and the control group's mean weight loss was just two percent.

All three groups followed a low calorie diet and exercise regimen for the duration of the study.

According to Dr. Maria Collazo-Clavel, an associate professor at College of Medicine, Mayo Clinic and medical editor of diabetes content on Mayo's health information website and for "Mayo Clinic The Essential Diabetes Book," the drug works mainly by suppressing appetite.

She says on the Mayo Clinic's website that the drug delays the passage of food from the stomach to the small intestine, increasing the amount of time in which the patient is satiated.

If approved for use as a weight loss medication, the drug could serve an important patient group.

"Weight loss and weight management are generally much harder for people who are overweight or obese and who also have type 2 diabetes," said Dr. Robert Kushner, Clinical Director, Northwestern Comprehensive Center on Obesity, Chicago. "Given the challenges faced by this patient population, the 5.9% weight loss seen with liraglutide 3 mg in this study is impressive.

Another positive result of the study was the reduction in blood glucose of 1.3% in the group that received liraglutide in the 3mg doses.

Some side effects, mostly gastro-intestinal complications such as nausea, were reported.

Danish pharmaceutical company Novo Nordisk is currently awaiting response from the Food and Drug Administration (FDA) and European Medicines Association (EMA) for approval as a weight management drug for overweight and obese adults.

Liraglutide is currently sold in the United States in smaller, injectable doses to control type 2 diabetes.

"There is a real need for effective treatment options for adults with obesity and type 2 diabetes that can demonstrate clinically meaningful weight loss and improve serious weight-related comorbidities," says Dr. Kushner.

View more news


Did you find what you were looking for on our website? Please let us know.

The contents of this site are for informational purposes only and are meant to be discussed with your physician or other qualified health care professional before being acted on. Never disregard any advice given to you by your doctor or other qualified health care professional. Always seek the advice of a physician or other licensed health care professional regarding any questions you have about your medical condition(s) and treatment(s). This site is not a substitute for medical advice.

© 1996 - 2014 MediResource Inc. - MediResource reaches millions of Canadians each year.